These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517 [TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and prognostic value of the Liu SY; Sun H; Zhou JY; Jie GL; Xie Z; Shao Y; Zhang X; Ye JY; Chen CX; Zhang XC; Zhou Q; Yang JJ; Wu YL Biomark Res; 2020; 8():22. PubMed ID: 32607238 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Implication of Noordhof AL; Swart EM; Damhuis RAM; Hendriks LEL; Kunst PWA; Aarts MJ; van Geffen WH JTO Clin Res Rep; 2023 Sep; 4(9):100543. PubMed ID: 37674812 [TBL] [Abstract][Full Text] [Related]
7. The Prevalence and Concurrent Pathogenic Mutations of Liu Y; Li H; Zhu J; Zhang Y; Liu X; Li R; Zhang Q; Cheng Y Cancer Manag Res; 2021; 13():2447-2454. PubMed ID: 33758543 [TBL] [Abstract][Full Text] [Related]
8. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent. Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080 [TBL] [Abstract][Full Text] [Related]
9. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations. Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study. Garcia BNC; van Kempen LC; Kuijpers CCHJ; Schuuring E; Willems SM; van der Wekken AJ Lung Cancer; 2022 May; 167():1-7. PubMed ID: 35349855 [TBL] [Abstract][Full Text] [Related]
11. The Prognostic Effect of Wahl SGF; Dai HY; Emdal EF; Berg T; Halvorsen TO; Ottestad AL; Lund-Iversen M; Brustugun OT; Førde D; Paulsen EE; Donnem T; Andersen S; Grønberg BH; Richardsen E Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503114 [TBL] [Abstract][Full Text] [Related]
13. KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry. Isaksson J; Berglund A; Louie K; Willén L; Hamidian A; Edsjö A; Enlund F; Planck M; Vikström A; Johansson M; Hallqvist A; Wagenius G; Botling J Clin Lung Cancer; 2023 Sep; 24(6):507-518. PubMed ID: 37296038 [TBL] [Abstract][Full Text] [Related]
15. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report. Iska S; Alley EW Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835 [TBL] [Abstract][Full Text] [Related]
16. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110 [TBL] [Abstract][Full Text] [Related]
17. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Sebastian M; Eberhardt WEE; Hoffknecht P; Metzenmacher M; Wehler T; Kokowski K; Alt J; Schütte W; Büttner R; Heukamp LC; Stenzinger A; Jänicke M; Fleitz A; Zacharias S; Dille S; Hipper A; Sandberg M; Weichert W; Groschek M; von der Heyde E; Rauh J; Dechow T; Thomas M; Griesinger F; Lung Cancer; 2021 Apr; 154():51-61. PubMed ID: 33611226 [TBL] [Abstract][Full Text] [Related]
18. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284 [TBL] [Abstract][Full Text] [Related]
19. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163 [TBL] [Abstract][Full Text] [Related]
20. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by Ruppert AM; Beau-Faller M; Debieuvre D; Ouafik L; Westeel V; Rouquette I; Mazières J; Bringuier PP; Monnet I; Escande F; Ricordel C; Merlio JP; Janicot H; Lemoine A; Foucher P; Poudenx M; Morin F; Langlais A; Souquet PJ; Barlesi F; Wislez M JTO Clin Res Rep; 2020 Sep; 1(3):100052. PubMed ID: 34589947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]